Pathophysiology, Diagnosis and Treatment of Immune Thrombocytopenia by Găman, Mihnea-Alexandru & Găman, Amelia Maria
The International Journal of Medical Students Int J Med Students   •   2017  |  Jan-Apr  |  Vol  5  |  Issue 132
IJMS
International Journal of 
Medical Students Review
Pathophysiology, Diagnosis and Treatment of Immune 
Thrombocytopenia
Mihnea-Alexandru Găman,1 Amelia Maria Găman1
Abstract
Immune thrombocytopenia (ITP) is an acquired disorder characterized by isolated thrombocytopenia with a peripheral blood count < 100.000/
mm3 in the absence of any obvious initiating or underlying causes, by antibody mediated destruction of platelets and suppression of me-
gakaryocyte and platelet production on the basis of immune deregulation. ITP is idiopathic (primary) in 80% of cases and secondary to several 
associated disorders in 20% of cases. A diagnosis of exclusion, based on patient history, physical examination, complete blood count and exami-
nation of the peripheral blood smear, is used for ITP. The treatment of ITP is indicated in adult patients with platelet counts below 20.000-30.000/
mm3, with bleedings or risk for bleeding. First line therapy is represented by corticosteroids, intravenous immunoglobulins and intravenous 
anti-RhD. Second-line treatment is represented by: splenectomy, inhibition of the monocytic phagocytic system therapy, immunosupressive 
therapy, anabolic steroids, anti-CD20 therapy, and thrombopoietin receptor agonists.
Keywords: primary immune thrombocytopenia, ITP, guidelines, thrombopoietin receptor agonists, splenectomy, immune thrombocytopenic 
purpura.
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Introduction
Immune thrombocytopenia (ITP) is an acquired disorder cha-
racterized by isolated thrombocytopenia with a peripheral 
blood count < 100.000/mm3 in the absence of any obvious 
initiating or underlying causes. 1 Immune thrombocytopenia 
may be idiopathic (primary) in 80% of cases and secondary to 
several associated disorders in 20% of cases: chronic or acute 
infections, vaccination, autoimmune disorders, immunodefi-
ciency diseases, lymphoproliferative diseases, drugs. The Im-
mune Thrombocytopenia International Working Group consen-
sus divided the disease into three phases: newly diagnosed ITP 
(less than 3 months from diagnosis), persistent ITP (between 3 
months - one year from diagnosis) and chronic ITP (more than 
one year from diagnosis). 2 The purpose of this manuscript is 
to review the literature regarding the pathophysiology, diagno-
sis and treatment of immune thrombocytopenia and to provide 
essential guidelines for students in medicine and young phy-
sicians, taking into consideration that few data is available on 
the management of patients suffering from ITP. 
Search Strategy and Selection Criteria
A literature search was computed by two independent inves-
tigators using the MEDLINE database, PubMed, and Google 
Scholar search services with the following key words and word 
combinations: immune thrombocytopenia, immune thrombo-
cytopenic purpura, ITP, ITP treatment, ITP guidelines, ITP pa-
thophysiology. Inclusion criteria incorporated relevant articles 
in English, published in between 1st January 2004 and 1st Au-
gust 2016, that addressed ITP as their main theme (pathophy-
siology, diagnosis and treatment). The educational program as 
well as congress abstracts of the European Hematology Asso-
1 "Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania.
ciation and ITP working group were also consulted for inclusion 
in this manuscript. The exclusion criteria were case reports, 
unavailability of any full article, unclear presentation, non-re-
levant studies and reports of different languages other than 
English. The common features were assembled into this pre-
sent review.
Pathophysiology
Although the pathophysiology of the primary ITP is still un-
clear, the disease is characterized by an antibody mediated 
destruction of platelets and a suppression of megakaryocyte 
and platelet production on the basis of immune deregulation. 
3, 4 Both genetic and environmental factors are involved in the 
production of autoantibodies. A predisposition to autoimmu-
nity, induced by genetic factors, exists and is associated with 
environmental factors (infection, inflammation, mimicry) which 
trigger an immune response represented by activated B cells, 
shifted Th1/Th2 balance, and increased phagocytic activity. 
Platelet-specific autoantibodies are directed against GPIIb/IIIa 
(which contains important B-cell and T-cell determinants and 
seven immunodominant epitopes), GP Ib/IX or other platelet 
glycoproteins. 4 Antiplatelet antibodies mediate the accelerated 
clearance from the circulation through the mononuclear phago-
cytic system. Cellular immunity is disturbed, T-cell and cytokine 
profiles are shifted towards a Th1/Th2, Tc1/Tc2 and Th17 pro-
inflammatory immune response and a reduction in suppressor 
T-regulatory cells is involved. 3
The pathophysiology of secondary immune thrombocytopenia, 
more complex than the one of the primary immune thrombo-
cytopenia, is cause dependent. In chronic infection with Heli-
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cobacter pylori, immune thrombocytopenia is the result of an-
tiplatelet autoantibodies produced by molecular mimicry to H. 
pylori antigens such as CagA, which induce platelet aggregation 
and platelet expresion of p-selectin and phosphatidylserine by 
some strains of H. pylori, associated with susceptibility to the 
infection of the human host (variation in Lewis antigens at the 
host mucosal surface, variation in the patient's individual HLA) 
and an increased phagocytic activity of monocytes and decrea-
sed FcγRIIb. Hepatitis C virus (HCV) and human immune defi-
ciency virus (HIV) can provoke anti-HCV and anti-HIV autoanti-
bodies respectively that cross-react with platelet glycoproteins 
and form immune complexes. 3 Acute infections (Epstein Barr 
virus, varicella zoster virus, influenza virus) or vaccination in-
duce immune thrombocytopenia by molecular mimicry and/or 
immune stimulation by specific antigen exposures that tip the 
immune response to break tolerance to platelets in susceptible 
persons. 3
Autoimmune disorders, such as systemic lupus erythematosus 
(SLE), antiphospholipid antibody syndrome and rheumatoid ar-
thritis are associated with immune thrombocytopenia are cha-
racterized by immune deregulation such as the shift in Th1/Th2 
balance, increased Th17, and altered T-cells regulatory profiles. 
Immune thrombocytopenia from SLE is determined by the anti-
GPIIb/IIa antibody-mediated platelet destruction and by the in-
hibition of megakaryopoiesis by antibodies directed against the 
thrombopoietin receptor (CD110, cluster of differentiation 110). 
5 Primary ITP is also a hematological feature of an auto-immune 
condition entitled antiphospholid syndrome, in which patients 
are at risk of developing arterial or venous thrombosis, as seen 
in a systematic review and meta-analysis conducted by Moulis 
et al. An association (strong if lupus anticoagulant was present, 
and weaker, but still present, if anticardiolipin antibodies were 
found) between the presence of antiphospholipid antibodies 
and the occurrence of arterial or venous thrombosis. 6
Some authors also believe that oxidative stress can be involved 
in the development of ITP, since reactive oxygen species that 
are excessively produced attack fundamental components of 
the cell such as proteins, which are highly immunogenic and 
may induce autoantibody production. 7, 8 In small group of 24 
patients, external administration of antioxidants via antioxidant 
supplements and a healthy diet improved therapeutic response 
and patient evolution. 9
Diagnosis
The first step in the diagnosis of immune thrombocytopenia is 
performing a blood marrow smear to confirm the low platelet 
count. If platelet aggregation is shown, a different anticoagu-
lant (EDTA versus citrate) must be used to rule out the possi-
bility of a false thrombocytopenia, a frequent clinical situation 
in practice. The diagnosis of immune thrombocytopenia is one 
of exclusion and is based on the patient’s history, physical 
examination, complete blood count and examination of the pe-
ripheral blood smear. 10 The evaluation of ITP requires a basic 
evaluation and additional tests of potential value. The basic 
evaluation is represented by: patient, family and medication 
history, physical examination, complete blood count, periphe-
ral blood film, quantitative immunoglobulins, bone marrow 
examination (in patients > 60 years old, those with systemic 
symptoms or when splenectomy is considered), blood group 
(Rh), H. pylori, HCV, and HIV tests. Additional tests which may 
have a potential value are represented by: antiphospholipid 
antibodies (Ig G and Ig M anti β2 GPI antibodies, Ig G and Ig 
M anti-cardiolipin antibodies), circulate lupus anticoagulant, 
thyroid stimulating hormone (TSH), antithyroid antibodies, 
antinuclear antibodies, anti-DNA antibodies, pregnancy test in 
women of childbearing years, polymerase chain reaction for 
parvovirus and cytomegalovirus (CMV). The determination of 
thrombopoietin, reticulated platelets, platelet associated im-
munoglobulin G, bleeding time, serum complement, platelet 
survival study have unproven benefits. Tests to rule out an 
important hematological emergency, disseminated intravascu-
lar coagulation, must be performed: prothrombin time, Kaolin 
time, fibrinogen, and platelet count. 
The Treatment of Primary Immune Thrombo-
cytopenia
Treatment is indicated in adult patients with platelet counts 
below 20.000-30.000/mm3, with bleedings or bleeding risk, 
trauma, surgery, anticoagulant therapy or patients whose pro-
fession/lifestyle predisposes to trauma. Therapy is used to in-
crease the platelet count to a safe level (50.000/mm3) and to 
prevent further bleeding with minimal toxicities. Most immune 
thrombocytopenic therapies suppress the active B-cells, T-cell 
and the mononuclear phagocytic system, and are likely to lead 
to the downregulation of inflammation and tipping of immune 
balance back towards tolerance. 3 The latest recommendations 
of the Immune Thrombocytopenia International Working Group 
consensus for ITP treatment are presented below.
First line therapy is represented by corticosteroids, intravenous 
immunoglobulins (IVIg) and intravenous (IV) anti-RhD. Corti-
costeroids (Dexamethasone 40 mg daily for four days every 
three weeks, or Methylprednisolone 30 mg/kg/day for seven 
days, or Prednisone 0.5-2 mg/kg/day for two-four weeks) used 
in combination with IVIg or IV anti-RhD rapidly increase platelet 
counts in patients with significant thrombocytopenia (<5.000/ 
mm3) and extensive bleeding. Corticosteroids globally influen-
ce the immune system by suppressing T-cell and B-cell reactivi-
ty while inducing tolerogenic patterns in T cells, dendritic cells 
and circulating cytokines. 3, 11 Toxicities vary with the length 
of administration, having a lower rate of side effects when a 
short-term bolus therapy is used (23% of patients have a sus-
tained response at 39 months). 2
Intravenous immunoglobulins or IVIg (0.4g/kg/day for five days 
or infusions of 1g/kg/day for one-two days) determined in 65-
80% of patients an increase of the platelet count within 24-48 
hours. 2, 10, 12 The mechanism of IVIg is unclear, but is thought 
to tip the immune balance back towards tolerance by inducing 
inhibitory phenotypes in the mononuclear phagocytic system 
(FcγRIIb) and possibly by inhibiting complement-mediated cell 
damage, suppressing B and T cells and exerting a direct an-
ti-idiotype effect on circulating functional antiplatelet autoanti-
bodies. 13 Sustained response is typically for three-four weeks, 
but may persist for months. Common toxicities are represen-
ted by hemolytic anemia, headaches, fever, chills, and infusion 
reactions. Rare toxicities are: aseptic meningitis, acute renal 
failure, thrombotic events. 
Intravenous anti-D (50-75μg/kg) has a similar dose-dependent 
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response rate to IVIg in four-five days. IV anti-D modulates 
FcγRs by blocking phagocytic cells via anti-Rh autoantibodies 
bound to erythrocytes and may modulate immunity by an-
ti-idiotype activity, Fc receptor modulation, cytokine shifts and 
downregulation of phagocytosis. Therapy significantly reduced 
the accelerated clearance of platelets with little effect on the 
platelet production. 14, 15 Common toxicities are represented by 
mild hemolytic anemia, headaches, fever. Rare toxicities are: 
intravascular hemolysis, renal failure, disseminated intravas-
cular coagulation, death. The concomitant use of corticoste-
roids may enhance the platelet response and reduce the side 
effects. 16
Second-line treatment is represented by: splenectomy, in-
hibition of the monocytic phagocytic system therapy (vinca 
alkaloid regimens), immunosupressive therapy (Azathioprine, 
Cyclosporin A, Cyclophosphamide), anabolic steroids (Dana-
zol), anti-CD20 therapy (Rituximab), TPO receptor agonists 
(Eltrombopag, Romiplostim). Splenectomy remains the treat-
ment option with the highest likelihood of producing cure. It 
is indicated by some authors as first line therapy in immune 
thrombocytopenia because the procedure appears to be a cu-
rative treatment. It is recommended to wait at least six mon-
ths from diagnosis before performing splenectomy due to the 
chance of spontaneous remission. Splenectomy removes a lar-
ge component of the mononuclear phagocytic system, the site 
of platelet sequestration, and also a lymphoid organ important 
for immune function, especially B-cell development and resto-
ration of T-cell variation. 3, 17 Splenectomy is associated with a 
better response in younger patients with no liver sequestration 
of platelets, 80% of patients responding to treatment in one 
to 24 days. Response is sustained with no additional therapy 
in approximately two-thirds over 5-10 years. The patients re-
quiring splenectomy must be vaccinated before splenectomy 
with antipneumococcal vaccine and after splenectomy should 
undergo Streptococcus pneumoniae, Haemophilus influenzae 
type B and Neisseria meningitidis vaccines to prevent sepsis. 
The complications of the procedure are: hemorrhage, peripan-
creatic hematoma, subphrenic abscess, wound infection, pneu-
mococcal infection, and thrombosis. Laparoscopic splenectomy 
reduced complication rates and is associated with faster reco-
very, but relapse can occur due to an accessory spleen which 
may require further surgical intervention. 18, 19 
Anti-CD20 therapy (Rituximab) decreases CD20-expressing 
B-cells and the shift to tolerance, increases regulatory T-cells, 
diminishes detectable oligoclonality in T-cell population, sti-
mulates CD110 and increases the platelet number. 17 It is used 
as the standard lymphoma regimen of 375mg/m2 weekly for 
four weeks. 20, 21 The optimal dose and frequency of rituximab 
administration for the treatment of immune thrombocytopenia 
is still unknown. 22 Sixty percent of patients obtained response 
(40% complete response) in one to eight weeks. Severe side 
effects include progressive multifocal leukoencephalopathy 
and reactivation of hepatitis B. Less serious toxicities include 
first-infusion reactions such as fever, chills and serum sick-
ness. 16
Cyclosporine A in dose of 2.5-3 mg/kg/day has immunomodu-
latory effects, a rate of response of 50-80% in small series and 
moderate and transient side effects. It increases platelet count 
alone or in combination with prednisone. Azathioprine has an 
immunomodulatory effect (40% response rate) and needs to 
be continued for three to six months. Toxicities have a low 
incidence and are in general mild. Cyclophosphamide induces 
response in 25-85% of patients in one to sixteen weeks with a 
sustained response up to 50%. 2 
Danazol and Dapsone are corticosteroid-sparing agents parti-
cularly useful in elder patients and at those to which splenec-
tomy is contraindicated.
Vinca alkaloid regimens have highly variable transient response 
in 10-75% of patients, with a response-time of five to seven 
days, an average of ten months sustained response and mode-
rate toxicities: neuropathy, neutropenia, fever, thrombophlebi-
tis or inflammation at the infusion site.
Thrombopoietin (TPO) receptor agonists have provided exce-
llent responses in both splenectomized and non-splenectomi-
zed patients. 2 They interact directly with the TPO receptor on 
megakaryocytes to stimulate platelet production and improve 
regulatory T-cell activity. 23 
Romiplostim is used in a dose of 1-10 μg/kg both in non-sple-
nectomized or splenectomized patients, with a response time 
of one to four weeks. It is a competitive inhibitor of TPO and 
binds directly to the TPO binding site on cMPL. 
Eltrombopag is used in a dose of 50 mg or 75 mg daily, with a 
response-time of 14 days. It may induce hepatotoxicity. Dizzi-
ness and reversible introversion have also been reported, but it 
seems that this TPO receptor agonist gives rise to less frequent 
and less severe side effects than corticosteroid therapy. 24, 25 
Side effects of TPO mimetics are represented by the develop-
ment of bone marrow reticulin fibrosis, venous thromboembo-
lism, myeloid malignancies, rebound thrombocytopenia, and 
headache.
The preferred approach on the treatment of secondary ITP is 
treating the underlying disease. Treatment regimens of ITP in 
patients failing first and second-line therapy are TPO mimetics 
and therapy with minimal data, considered to have potential 
or considerable toxicities: campath-1H (fever, chills, rigor, intra-
cranial hemorrhage, cerebral vein thrombosis, infection, severe 
intravascular hemolysis, death), combination chemotherapy 
(risk of secondary malignancies, pancytopenia, hemorrhagic 
cystitis, neuropathy), hematopoietic stem cell transplantation 
(myelosuppresion, infection, graft-versus host disease, muco-
cutaneous bleeding, death).
The treatment of ITP in pregnancy - corticosteroids or IVIg are 
recommended as first line therapy in the first two trimesters 
when the patient is symptomatic and if the platelet count falls 
below 20-30.000/mm3. Splenectomy is rarely indicated in preg-
nancy, but is the best option in the second trimester if ab-
solutely necessary. 2 In neonates with clinical hemorrhage or 
platelet counts below 20.000/mm3, therapy with a single dose 
of IVIg 1g/kg induces a rapid response. Rituximab, vinca alka-
loids, danazol, TPO-mimetics should be avoided in pregnancy 
due to teratogenicity.
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The emergency therapy requires a high-dose of intravenous 
corticosteroids and IVIg or, as alternative, platelet transfusion 
with or without IVIg, vinca alkaloids, emergency splenectomy 
and anti-fibrinolytics.
Conclusions
The current manuscript reviews the therapeutic guidelines re-
commended by international experts in patients with immune 
thrombocytopenia in order to improve treatment outcome as 
data regarding the management of such patients is relatively 
scarce. However, there are studies in the medical literature 
that report several degrees of inappropriateness in how these 
guidelines are put into practice as, in some cases, recommen-
dations do not always address all the therapeutical obstacles 
that the clinician encounters when diagnosing and treating pa-
tients with ITP. 26
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